Ejaz Khan, MD
Internal Medicine · Upper Marlboro, MDNPI 1669416160
Payments from drug & device makers
Across 324 payments — averaging $217.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51K
- Biosense Webster, Inc.$11K
- Boston Scientific$3K
- AstraZeneca$566
- Philips North America LLC$544
- Medtronic$543
- plus $4K from 33 others
What the payments were for
- Consulting fees$2,85014%
- Travel & lodging$8,41142%
- Food & beverage$8,49443%
- Education$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 37 | $51,301 |
| Biosense Webster, Inc. | 33 | $10,615 |
| Boston Scientific | 56 | $2,947 |
| AstraZeneca | 18 | $566 |
| Philips North America LLC | 13 | $544 |
| Medtronic(2 entities) | 24 | $543 |
| E.r. Squibb & Sons, L.L.C. | 15 | $518 |
| Novartis | 23 | $394 |
| Atricure, Inc. | 5 | $382 |
| Novo Nordisk | 15 | $344 |
| Abbott | 5 | $340 |
| Amgen | 9 | $253 |
| Johnson & Johnson(2 entities) | 11 | $230 |
| Pfizer | 9 | $194 |
| Baxter Healthcare | 3 | $177 |
| Esperion Therapeutics, Inc. | 2 | $131 |
| Amarin Pharma, Inc. | 3 | $129 |
| Alnylam Pharmaceuticals Inc. | 6 | $117 |
| Scpharmaceuticals Inc. | 4 | $108 |
| Cardiva Medical, Inc. | 4 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Heartflow, Inc. | 3 | $61 |
| Exact Sciences | 2 | $59 |
| Lilly USA, LLC | 2 | $52 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Cvrx, Inc. | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 2 | $37 |
| Cleerly, Inc. | 1 | $35 |
| Abiomed | 2 | $34 |
| Penumbra, Inc. | 1 | $31 |
| Medicomp Inc | 1 | $28 |
| Recor Medical Inc | 1 | $26 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3 System$9,593
- Carto Smarttouch$9,593
- Carto CFAE$9,593
- CartoSound$9,593
- GENERAL - THERAPIES$1,124
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$286
- (9520) IGT Devices Undivided$250
- FARXIGA$242
- Carto 3$239
- Repatha$125
- NEXLIZET$120
- NEXLETOL$120
- AMPLATZER AMULET$113
- CAMZYOS$111
- Vascepa$109
How this compares
$70,547 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $159,159 |
| XareltoRivaroxaban | 20 | $26,962 |
| MultaqDronedarone Hcl | 11 | $11,655 |
| Metoprolol Succinate | 58 | $1,058 |
| Flecainide Acetate | 46 | $1,004 |
| Bumetanide | 11 | $513 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $441 |
| Propranolol Hcl | 20 | $436 |
| Valsartan | 13 | $423 |
| Atorvastatin Calcium | 42 | $369 |
| ClopidogrelClopidogrel Bisulfate | 19 | $327 |
| SotalolSotalol Hcl | 12 | $307 |
| Amlodipine Besylate | 67 | $306 |
| Nebivolol Hcl | 11 | $306 |
| Losartan Potassium | 28 | $292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $194 | $159,159169 claims |
| Johnson & JohnsonXarelto | $230 | $26,96220 claims |
| Sanofi-aventis U.S. LLCMultaq | $68 | $11,65511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Upper Marlboro
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.